Latest Shire PLC News and Updates
Travis Perkins Rebounded, Led EWU by 5.09%
Travis Perkins was at the top of the iShares MSCI United Kingdom ETF on October 23, 2015, as analysts showed positivity toward the construction industry.
AQR Capital increases stake in Intel
Intel generated ~$5.7 billion in cash from operations. The company paid quarterly dividends of $1.1 billion and repurchased 122 million shares for $4.2 billion.
Adage Capital adds a new position in Mallinckrodt
Adage Capital added a new position in Mallinckrodt Plc (MNK) in the third quarter of 2014. The position accounted for 0.82% of the fund’s total portfolio.
Pfizer’s Medivation Acquisition: What You Need to Know
On August 22, Medivation (MDVN) and Pfizer (PFE) entered into a definitive agreement. Pfizer will acquire Medivation for a consideration of ~$14 billion.
American Airlines gets significantly lower position in Appaloosa
Appaloosa Management significantly lowered its position in American Airlines (AAL) in the third quarter that ended in September 2014. The position accounts for 3.81% of the fund’s total third-quarter portfolio.
Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug
Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.
AQR Capital initiated position in Bally Technologies Inc.
AQR Capital initiated a position in Bally Technologies during the third quarter of 2014 that accounts for 0.22% of the fund’s 3Q14 portfolio.
Buy Allows Horizon to Further Expand into Orphan Drug Space
Through the acquisition of Raptor Pharmaceuticals, Horizon Pharma (HZNP) will gain access to Procysbi and Quinsair and expand in the orphan drug space.
BioMarin Leads in the Market for Mucopolysaccharidoses Disorders
BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.
What Bob Doll Thinks about the IPO Market in 2017
Equity market indexes across the United States are surging and recording all-time highs. The volatility index is also falling, which could be a good sign for IPO activity in 2017.
How Alexion Plans to Fuel Strensiq Sales
With the Enobia acquisition in February 2012, Alexion benefited in long-term disease awareness, diagnostic planning, and initiatives in the HPP space.
Lyrica to Lose Patent Protection in the US in 2018
After Pfizer lost patent protection for Lipitor, Lyrica became increasingly important to it. During its peak in 2014, Lyrica added $5.2 billion to Pfizer’s top line.
Shire Gets Dropped from AQR Capital’s Portfolio
During the fourth quarter of 2014, AQR Capital closed its position in Shire plc (SHPG). The fund sold its entire stake of 816,116 shares in the company.
Sector Composition Changes in FHJUX until 1Q16
FHJUX’s assets were spread across 73 holdings as of March 2016, which is six less than a quarter ago. It was managing assets worth $1.3 billion as of the end of March.
NXP Semiconductors is Appaloosa Management’s new position
Appaloosa Management initiated a new position in NXP Semiconductors NV (NXPI) in the third quarter that ended in September 2014. The position accounts for 2.55% of the fund’s total third-quarter portfolio.
A key overview of Adage Capital’s holdings in 3Q14
Adage Capital’s US long portfolio grew from $38.69 billion in 2Q14 to $40.2 billion in 3Q14. The portfolio comprised around 699 stocks.
Kinder Morgan’s position with Adage Capital eliminated
Adage Capital exited a position in Kinder Morgan Inc (KMI) in the third quarter. The position accounted for 0.37% of the fund’s total 2Q portfolio.
Citigroup gets raised position with Adage Capital
Adage Capital raised its position in Citigroup Inc. (C) in the third quarter. The position accounted for 0.98% of the fund’s total 3Q portfolio.
Adage Capital raises its position in NiSource
Adage Capital raised its position in NiSource Inc. (NI) in the third quarter. The position accounted for 0.52% of the fund’s total 3Q14 portfolio.
Whirlpool’s position upped in Appaloosa Management
Appaloosa Management upped its position in Whirlpool Corporation (WHR) in the third quarter that ended in September 2014. The position accounts for 4.29% of the fund’s total third-quarter portfolio.
Appaloosa exits position in Expedia
Appaloosa Management exited a position in Expedia, Inc (EXPE) in the third quarter that ended in September 2014. The position accounted for 0.99% of the fund’s total portfolio in the second quarter.
Jazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?
Jazz Pharmaceuticals’ Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017.
Recommendations for Shire as of October 30
Analysts’ estimates show that Shire (SHPG) stock has a potential to return ~15.8% over the next 12 months.
Shire: Why Analysts Expect Revenue Growth in Q3 2018
Analysts are expecting Shire (SHPG) to report a 3.3% growth in revenue when it reports its third-quarter earnings on November 1.
What to Expect from Thermo Fisher’s Third-Quarter Earnings
Thermo Fisher Scientific (TMO), a leading life sciences company, is scheduled to release its third-quarter earnings on October 24.
GW Pharmaceuticals: Recommendations and Market Capitalization
Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.
Novartis ADR’s Performance and Revenue Estimates for Q3 2018
Novartis’s (NVS) stock price has increased ~14.3% in the third quarter, and its stock rose ~2.8% year-to-date on October 2.
Estimates and Recommendations for Shire on September 19
Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.
Shire’s Quarterly Revenue Trend
Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter.
A Look at Shire’s Valuation on September 19
Shire reported adjusted EPS of $3.88 on revenue of ~$3.9 billion in the second quarter, a 4.6% YoY (year-over-year) rise.
Shire’s Q2 2018 Earnings Beat Analyst Estimates
Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018.
What to Expect from Shire’s Q2 2018 Earnings on July 31
Shire (SHPG) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS of $3.67 on revenues of $3.8 billion.
How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?
BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.
Takeda Pharmaceutical Makes 4th Successive Bid for Shire
Takeda Pharmaceutical’s (TKPYY) bid for Shire (SHPG) has piqued a lot of investor interest.
No Bid Coming for Shire Reportedly
Will Allergan buy Shire? – Apparently not CNBC saying no bid is likely. Allergan is off its lows – only down $5 now and Shire is back to flat after being up as much as $15 (~10%) earlier. From earlier: Shire PLC (NASDAQ: SHPG) is up 4.5% as of 11:10 A.M. on Thursday following an announcement […]
Alexion Pharmaceuticals in 4Q17 and Fiscal 2017
In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.
How Is Bioverativ’s Eloctate Positioned Now?
In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.
How Is Roche’s Hemlibra Positioned for 2018?
Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.
How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.
Venator to Participate in Food Ingredients Europe
Venator, a spin-off of Huntsman (HUN), rose 0.80% and closed at $23.28 for the week ending November 24, 2017. The stock was listed on August 3, 2017.
How Are Bioverativ’s Key Drugs Positioned after 2Q17?
In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.
Erwinaze Sales May Remain Flat in 2017
Erwinaze saw net sales worth $49 million in 2Q17, almost flat compared to the drug’s revenues of $50 million in 2Q16.
Bioverativ’s Research Pipeline May Boost Future Revenues
Bioverativ (BIVV) plans to improve compliance rates for hemophilia patients further by launching therapies with lower dosage frequency.
Bioverativ’s Eloctate Sees More Demand from Hemophilia A Patients
In 1Q17, Bioverativ’s Eloctate witnessed revenues close to $155.9 million, which is about $48.0 million more YoY (year-over-year).
Why More Companies Want to Stay Private
The equity markets across the US (SPY) (QQQ) are surging with indexes recording all-time highs in 2017.
Valeant’s Salix Acquisition Saga
Valeant won the acquisition race for Salix by valuing it at $14.5 billion, inclusive of net debt. In April 2015, Valeant paid $158 per Salix share.
Looking at the Portfolio of the Fidelity Advisor Europe Fund
Industrials and financials are the top two invested sectors of FHJUX, and each sector commands more than one-fifth of the portfolio.
Eli Lilly and Co.’s 3Q16 Estimates: Neuroscience Franchise
Another franchise from Eli Lilly and Co.’s (LLY) human pharmaceuticals segment is the neuroscience franchise.
How Gilead Dominates the HCV Space
In January 2012, Gilead Sciences (GILD) acquired Pharmasset and got access to sofosbuvir. In December 2013, the FDA approved sofosbuvir under the brand name Sovaldi.
Why Are Revenues from Pfizer’s Rare Disease Portfolio Falling?
BeneFIX, the major contributor to Pfizer’s (PFE) Rare Disease portfolio, is indicated for hemophilia B. During the first six months, the drug earned $367 million.
How Pfizer’s Internal Medicine Core Drugs Are Performing
The major contributors in Pfizer’s (PFE) Internal Medicine business include Lyrica and Viagra. Lyrica’s Innovative Health (or IH) contribution to the Internal Medicine portfolio stood at 48%.
How Significant Is Alexion’s Opportunity with Soliris?
Alexion (ALXN) has been serving the atypical hemolytic uremic syndrome, or aHUS, market for the past five years.
How Will Shire’s LSD Portfolio Perform in 2016?
Shire’s (SHPG) LSD (or lysosomal storage disorders) portfolio consists of Elaprase, Replagal, and Vpriv.
Inside Lilly’s 2Q16 Estimates for Its Neuroscience Franchise
Another franchise in Eli Lilly’s Human Pharmaceuticals segment is the neuroscience franchise, which contributes ~13% of Lilly’s total revenues.
Regeneron’s Dupilumab: How Much Potential Does It Hold?
Dupilumab has a breakthrough therapy designation from the FDA for the indication of moderate-to-severe atopic dermatitis in adults.
The Truth behind Horizon’s EV-to-EBITDA Performance
On June 29, 2016, Horizon Pharma was trading at a forward EV-to-EBITDA multiple of 4.67x, which is at a discount when compared with peers.
BioMarin Withdraws Application for Kyndrisa: Stock Falls 2.5%
As of June 1, 2016, BioMarin Pharmaceutical (BMRN) was the most underperforming stock among the large-cap stocks of the SPDR S&P Biotech ETF (XBI).
Shire’s Shareholders Approve Baxalta Merger: What’s Next?
Shire (SHPG) performed the worst among the large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) on May 27, 2016.
Timely Energy Exposure Helped FHJUX in 1Q16
The Fidelity Advisor Europe Fund – Class A (FHJUX) fell 1.8% in 1Q16. But it still emerged as an above-average performer among the 12 funds in this review.
How Does Shire Lead the Angioedema Space?
Cinryze and Firazyr are Shire’s (SHPG) two drugs in its hereditary angioedema portfolio. Together, these two drugs crossed $1 billion in sales in fiscal 2015.
The Shire-Baxalta Merger: A Look at the Details
Following news of the Shire-Baxalta merger, Baxalta’s share price rose and Shire’s share price fell.
Defitelio: Volume and Pricing Challenges
Jazz Pharmaceuticals’ Defitelio is the first and only approved treatment that increases survival in VOD patients with multi-organ dysfunction (or MOD).
What’s Happening with a Generic Version of Vyvanse?
Vyvanse, Shire’s (SHPH) key drug, earned $1.7 billion in 2015, a 21% annual growth. Analysts expect Vyvanse to add $1.9 billion and $2.1 billion to Shire’s top line in 2016 and 2017.
How Vyvanse Could Fuel Shire’s ADHD Portfolio Sales
Vyvanse is Shire’s leading ADHD drug, constituting 80% of the company’s ADHD portfolio. In fiscal 2015, Vyvanse earned the company $1.7 billion.
Analysts Are Optimistic About Shire
According to a Bloomberg consensus of 15 brokerage firms, 86.7% of analysts rated Shire a “buy,” and 13.3% rated it a “hold.” None issued a “sell” rating for the stock.
Why Did Shire Fall after Shire-Baxalta Acquisition Announcement?
On January 11, 2016, Shire (SHPG) announced a merger agreement with Baxalta for a whopping $32 billion. The Shire-Baxalta deal is still in progress and should close by mid-2016.
Shire at Discount on Price-to-Earnings Basis: A Good Opportunity?
With estimated double-digit sales growth and post-Baxalta-acquisition synergies, Shire’s PE could rise in the near term and result in a rise in share price.
Shire’s Acquisition Gives It Natpara and Gattex
Gattex is the first and only analog of glucagon-like peptide-2 (or GLP-2) indicated for short bowel syndrome. The drug is known as Gattex in the United States and Revestive in Europe.
An Above-Average Year for FHJUX
FHJUX’s quantitative metrics place it as an above-average performer for the one-year period ended March 15, 2016. This period covers two major stimulus announcements by the ECB.
Orkambi: Recent Addition to the Vertex Portfolio
In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for treating cystic fibrosis in the United States for patients 12 years and older with two copies of the F508del mutation.
The Baxalta–Shire merger: Basics of Shire Pharmaceuticals
Shire is a biopharmaceutical company that focuses on rare diseases. Shire is best known for its treatments in ADHD, and the market here is quite large.
How the Fidelity Advisor Europe Fund Allocated Its Portfolio in 2015
The Fidelity Advisor Europe Fund was managing assets worth $1.4 billion as of the end of December.
Vertex Pharmaceuticals: What Are Analysts’ Estimates?
Vertex Pharmaceuticals will report earnings for 4Q15 and fiscal 2015 on January 27, 2016. The company’s major focus area is hereditary disorder cystic fibrosis (or CF).
Growth and Synergies Drive the Baxalta–Shire Merger
The Baxalta–Shire merger could create the top platform for rare diseases in the world. Baxalta brings Advate, a treatment for hemophilia, a rare blood disease.
Naglazyme: One of the Costliest Drugs in the United States
The wholesale cost per patient for Naglazyme is around $485,747 per year. The drug has been effective in improving walking and stair-climbing capacity.
US Stock Indexes Fell in December amid Falling Oil Prices
Let’s see why US stock indexes fell. The three US equity indexes that we review in this December recap series fell from November 30 to December 31, 2015.
Celgene Falls on Profit Booking, IBB Large-Caps Fall by 0.5%
Celgene (CELG) fell by 2.5% on December 28, 2015. The stock fell on profit booking after it closed at $122.07 on December 23, 2015.
The SPDR S&P Biotech ETF Lingers in the Red as of December 3
The SPDR S&P Biotech ETF (XBI) went down by 3.9% on December 3, which represents the third consecutive day of declines for the ETF. XBI closed at $68.91.
The Fidelity Advisor Europe Fund: Class A (FHJUX)
As of August 2015, the Fidelity Advisor Europe Fund was managing assets worth $1.45 billion. Founded in 1986, the fund’s net expense ratio is 1.35%.
Top Ten XBI Stocks by Market Cap Outperform August 25–31
The top ten stocks of the SPDR S&P Biotech ETF (XBI) outperformed the top ten stocks of the iShares Nasdaq Biotechnology ETF (IBB) and the Health Care Select Sector SPDR ETF (XLV) for August 25–31.
How Does Vertex Compare to Its Peers?
Though Vertex is trading close to the upper Bollinger Band, the stock doesn’t seem to be in the overbought position and is poised for long-term growth.
AQR Capital Begins a Position in Flextronics International
AQR Capital commenced a position in Flextronics International (FLEX). FLEX represented 0.3% of the fund’s 4Q14 portfolio.
AQR Capital Trades Key Positions in its 4Q14 Portfolio
The size of the AQR Capital Management’s portfolio was $48.2 billion in 4Q14, up from $36.4 billion in 3Q14.
Paulson & Co. adds to its position in Mylan
In July, Mylan said it would acquire Abbott Laboratories’ (ABT) non-US developed markets specialty and branded generics business.
D.E. Shaw ups its position in AbbVie
AbbVie develops and markets advanced therapies that address some of the world’s most complex and serious diseases.
Farallon Capital starts new position in Cognizant Tech Solutions
During the third quarter, Farallon Capital Management initiated a position in Cognizant Technology Solutions (CTSH). The position accounted for 2.06% of the fund’s 3Q14 portfolio.
Adage Capital adds stake in Duke Energy
Adage Capital added a new position in Duke Energy in the third quarter. The position accounted for 0.20% of the fund’s total 3Q portfolio.
TRW Automotive Holdings is Adage Capital’s new position
Adage Capital added a new position in TRW Automotive Holdings, which accounted for 0.32% of the fund’s total 3Q14 portfolio.
AQR Capital sold its stake in Riverbed Technology
On October 27, NetApp announced the acquisition of Riverbed’s SteelStore product line in an all-cash transaction for approximately $80 million.
AQR Capital sold its position in AstraZeneca
AstraZeneca is one of a few pure-play bio-pharmaceutical companies that span a medicine’s entire value chain.
AQR Capital ups position in Glimcher Realty Trust
Glimcher Realty Trust is one of the leading real estate investment trusts or REITs. It owns, manages, and develops a portfolio of retail properties.
AQR Capital raises position in Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative medicines for life-threatening illnesses around the world.